Newsletter Vol. 2, No. 3 References

Clinical Corner References

Feature Article References

1. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005;65:1621-1650.

2. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004;1:292-300.

3. Billups KL, Bank AJ, Padma-Nathan H, Katz S, Williams R. Erectile dysfunction is a marker for cardiovascular disease: results of the Minority Health Institute Expert Advisory Panel. J Sex Med. 2005;2:40-52.

4. Rosano GM, Aversa A, Vitale C, Fabbti A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005;47:214-220.

5. Buvat J, van Ahlen H, Schmitt H, Chan M, Keupfer C, Varanese L. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. J Sex Med. 2006;3:512-520.

6. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2:415-427.

7. Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50:351-359.

8. Sadovsky R, Dunn M, Grobe BM. Erectile dysfunction: the primary care practitioner’s view. Am J Manag Care. 1999;5:333-341.

9. Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for “non-responders” to tadalafil and vardenafil: a real-life study. Eur Urol. 2006;50:126-133.

10. Ralph D, McNicholas T, for the Erectile Dysfunction Alliance. UK management guidelines for erectile dysfunction. BMJ. 2000;321:499-503.

11. Sadovsky R, Miller T, Moskowitz M, Hackett G. Three-year update of sildenafil citrate (Viagra^®) efficacy and safety [review]. Int J Clin Pract. 2001;55:115-128.

12. Viagra (sildenafil) prescribing information. Pfizer Inc: New York, NY; 2005.

13. Levitra (vardenafil) prescribing information. Bayer Pharmaceuticals Corp: West Haven, Conn; 2005.

14. Cialis (tadalafil) prescribing information. Lilly ICOS LLC: Indianapolis, Ind and Bothell, Wash; 2005.

15. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl. 2001;22:793-797.

16. Guay AT, Spark RF, Bansal S, et al, for the AACE Male Sexual Dysfunction Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple’s problem—2003 update. Endocr Pract. 2003;9:77-95.

17. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Testosterone replacement therapy with testosterone-gel 1% converts sildenafil non-responders to responders in men with hypogonadism and erectile dysfunction who failed prior sildenafil therapy. J Urol. 2003;169(suppl):247. Abstract 954.

18. Rajfer J, Aliotta PJ, Steidle CP, Fitch III WP, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res. 2006 Jul 27; [Epub ahead of print].

19. Montorsi F, Padma Nathan H, McCullough A, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol. 2004;172:1036-1041.

20. Levine LA, McCullough AR, Padma-Nathan H. Longitudinal randomized placebo-controlled study of the return of nocturnal erections after nerve-sparing radical prostatectomy in men treated with nightly sildenafil citrate. J Urol. 2004;171(suppl):231-232. Abstract 875.

21. Roehrborn CG, McVary KT, Kaminetsky JC, et al. The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). J Urol. 2006;175(suppl):527. Abstract 1636.

22. McVary KT, Swierzewski MJ, Monnig WB, et al. Sildenafil improves erectile function and concomitant lower urinary tract symptoms in men. J Urol. 2006;175(suppl):298. Abstract 920.

23. Sairam K,  Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90:836-839.

24. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol. 2001;166:569-575.

25. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelman U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey.’ Int J Impot Res. 2000;12:305-311.

26. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T, and the Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes. Diabetes Care. 2003;26:777-783.

27. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-1813.

28. Penson DE, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the exploratory comprehensive evaluation of erectile dysfunction (ExCEED) database. Diabetes Care. 2003;26:1093-1098.

29. Costabile RA. Optimizing treatment for diabetes mellitus induced erectile dysfunction. J Urol. 2003;170:S35-S39.

30. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia. 2004;47:1914-1923.

31. Padma-Nathan H, McCullough A, Forest C. Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep. 2004;5:467-471.

32. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol. 2003;44:637-649.

33. Carson CC III, and the International Conference on BPH and Sexuality in the Aging Male. Managing sexual dysfunction in the BPH patient. Contemp Urol. 2004:25-33.

Clinical Corner References

1. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004;1:292-300.

2. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2:415-427.

3. Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for “non-responders” to tadalafil and vardenafil: a real-life study. Eur Urol. 2006;50:126-133.

4. Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50:351-359.

5. Padma-Nathan H, McCullough A, Forest C. Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep. 2004;5:467-471.